Evidence map›Paper›PMID 27108303›Full record

ArticleFamilial cancer2016

Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families.

Jazlyn Read, Judith Symmons, Jane M Palmer, Grant W Montgomery, Nicholas G Martin, Nicholas K Hayward

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jazlyn ReadQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia. jazlyn.read@qimrberghofer.edu.au.
Judith SymmonsQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia.
Jane M PalmerQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia.
Grant W MontgomeryQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia.
Nicholas G MartinQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia.
Nicholas K HaywardQIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Herston, Brisbane, QLD, 4029, Australia.
QIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial cancer risk has been proposed as a shared feature of many cancers, and overall susceptibility is influenced by combinations of low to moderate risk polymorphisms, rare high penetrance germline mutations, and modulation of risk by environmental and genetic factors. Clustering of melanoma occurs in approximately 10 % of families, and an over-representation of additional cancers has been noticed in some 'melanoma' families. The degree to which other cancers aggregate in families affected by melanoma has not been well defined. Therefore, this study aimed to assess the risk of cancers other than melanoma in a cohort of 178 'intermediate risk' melanoma families, not selected for specific genetic mutations. Families designated as 'intermediate risk' had two first degree relatives (FDRs) affected by melanoma when ascertained between 1982 and 1990, and were followed up over a 33 year period to assess new occurrences of cancer. We included 414 melanoma cases and 529 FDRs, comprising 25,264 person years of observation. Standardised incidence ratios and their 95 % confidence intervals were calculated for all invasive cancers, comparing observed to expected cases of cancer based on age and sex specific incidence rates for the Queensland population. Statistically significant increases were found for bladder cancer in females (observed, 7; expected, 1.99; SIR, 3.52; 95 % CI 1.41-7.25), lymphoid leukaemia in females (observed, 6; expected, 1.75; SIR, 3.43; 95 % CI 1.26-7.46), and myeloma in female melanoma cases (observed, 4; expected, 0.82; SIR, 4.89; 95 % CI 1.33-12.52). Over-representation of bladder cancer, lymphoid leukaemia, and myeloma in females of the cohort may suggest sex-dependent co-modifiers, and it is possible that specific combinations of polymorphisms predispose to certain cancer types.

Indexed as

Cohort StudiesCutaneous Malignant MelanomaFemaleHumansIncidenceLeukemia, LymphoidMaleMelanomaPedigreeQueenslandSkin NeoplasmsUrinary Bladder NeoplasmsBladder cancerFamilial cancerLymphoid leukaemiaMelanomaRisk

Identifiers

PMID27108303
OpenAlexW2336740320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.